Kiniksa Pharmaceuticals International (KNSA) Net Margin (2021 - 2026)

Kiniksa Pharmaceuticals International has reported Net Margin for 6 years, with the latest figure at 10.54% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 435.0% year-over-year to 10.54%; the trailing twelve-month figure through Mar 2026 stood at 9.69% (up 1162.0% YoY), and the FY2025 full-year result was 8.71%, up 1710.0% from the prior year.
• Net Margin for Q1 2026 stood at 10.54%, up from 7.02% in the prior quarter.
• The five-year high for Net Margin was 226.05% in Q3 2022, with the low at 99.56% in Q4 2023.
• Historically, Net Margin has averaged 1.02% across 5 years, with a median of 0.99% in 2024.
• Annual changes were most pronounced in 2022 — Net Margin surged 47858 bps — and 2023, when it slumped 24671 bps.
• Kiniksa Pharmaceuticals International's Net Margin stood at 61.12% in 2022, then sank by 263 bps to 99.56% in 2023, then surged by 99 bps to 0.99% in 2024, then surged by 809 bps to 7.02% in 2025, then surged by 50 bps to 10.54% in 2026.
• The last three Net Margin figures came in at 10.54% (Q1 2026), 7.02% (Q4 2025), and 10.19% (Q3 2025), per Business Quant data.